Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2002-01-15
2009-11-03
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S329000, C530S328000, C530S327000, C530S326000, C530S325000, C530S324000, C530S317000, C530S323000, C530S391100, C530S391700, C424S001570, C424S001690, C424S192100, C424S193100, C514S011400, C514S019300
Reexamination Certificate
active
07611711
ABSTRACT:
The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.
REFERENCES:
patent: 4975278 (1990-12-01), Senter et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 5952199 (1999-09-01), Davis-Smyth
patent: 6040157 (2000-03-01), Hu et al.
patent: 6100071 (2000-08-01), Davis-Smyth
patent: 6107046 (2000-08-01), Alitalo et al.
patent: 6121416 (2000-09-01), Clark et al.
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6331302 (2001-12-01), Bennett
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6383484 (2002-05-01), Achen et al.
patent: 6383486 (2002-05-01), Davis-Smyth
patent: 6403088 (2002-06-01), Alitalo
patent: 6451764 (2002-09-01), Lee et al.
patent: 6576608 (2003-06-01), Lee et al.
patent: 6608182 (2003-08-01), Rosen et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6673343 (2004-01-01), Bennett et al.
patent: 6689580 (2004-02-01), Achen et al.
patent: 6730489 (2004-05-01), Achen et al.
patent: 6730658 (2004-05-01), Alitalo et al.
patent: 2001/0038842 (2001-11-01), Achen et al.
patent: 2002/0048763 (2002-04-01), Penn et al.
patent: 2002/0065218 (2002-05-01), Achen et al.
patent: 2002/0102260 (2002-08-01), Achen et al.
patent: 2002/0120123 (2002-08-01), Rosen et al.
patent: 2002/0123481 (2002-09-01), Oliviero
patent: 2002/0127222 (2002-09-01), Achen et al.
patent: 2002/0146420 (2002-10-01), Bennett et al.
patent: 2002/0151489 (2002-10-01), Gravereaux et al.
patent: 2002/0182683 (2002-12-01), Hu et al.
patent: 2002/0197691 (2002-12-01), Sugiyama
patent: 2003/0008357 (2003-01-01), Hu et al.
patent: 2003/0028007 (2003-02-01), Hu et al.
patent: 2003/0091567 (2003-05-01), Alitalo et al.
patent: 2003/0092604 (2003-05-01), Davis-Smyth et al.
patent: 2003/0125537 (2003-07-01), Achen et al.
patent: 2003/0166523 (2003-09-01), Achen et al.
patent: 2003/0166547 (2003-09-01), Oliviero
patent: 2003/0166873 (2003-09-01), Lee et al.
patent: 2003/0170786 (2003-09-01), Rosen et al.
patent: 2003/0175274 (2003-09-01), Rosen et al.
patent: 2003/0176674 (2003-09-01), Rosen et al.
patent: 2003/0180294 (2003-09-01), DeVries
patent: 2003/0211101 (2003-11-01), Wise et al.
patent: 2003/0211988 (2003-11-01), Epstein
patent: 2003/0215921 (2003-11-01), Coleman
patent: 2003/0228283 (2003-12-01), Heinzerling et al.
patent: 2003/0232437 (2003-12-01), Zhang et al.
patent: 2004/0037820 (2004-02-01), Alitalo et al.
patent: 0935001 (1999-08-01), None
patent: WO 96/26736 (1996-09-01), None
patent: WO 97/12972 (1997-04-01), None
patent: WO 98/02543 (1998-01-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/33917 (1998-08-01), None
patent: WO 99/25869 (1999-05-01), None
patent: WO 99/30157 (1999-06-01), None
patent: WO 99/40947 (1999-08-01), None
patent: WO 99/60025 (1999-11-01), None
patent: WO 00/21560 (2000-04-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO 00/52054 (2000-09-01), None
patent: WO 00/62063 (2000-10-01), None
patent: WO 01/52875 (2001-07-01), None
patent: WO 2004/009773 (2004-01-01), None
Lee et al, Proc Nat. Acad. Sci USA 93: 1988-1992, Mar. 1996.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Curnis et al, Nat Biotechnol 18(11): 1185-90, Nov. 2000.
Hirohashi et al, Mol Pharmacol 53(6): 1068-75, Jun. 1998.
Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.
Baldwin et al, J Biol Chem 276(22): 19166-19171, 2001.
Mason et al, Molecular Endocrinology 8(3): 325-332, 1994.
Yamada et al, Blood 97(6): 1671-1678, Mar. 2001.
Dermer et al, Bio/Technology 12; 320, 1994.
Gura et al, Science 278: 1041-1042, 1997.
Achen, et al.,Proc. Nat'l. Acad. Sci. USA, 95:548-553 (1998).
Achen, et al.,Eur. J. Biochem., 267(9):2505-2515 (2000).
Aprelikova, et al.,Cancer Res., 52:746-748 (1992).
Banerji, et al.,J. Cell Biol., 144:789-801 (1999).
Bellomo, et al.,Circ. Res., E-29-E35 (2000).
Breier, et al.,Dev., 114:521-532 (1992).
Cao et al.,J. Biol. Chem., 271:3154-3162 (1996).
Dumont, et al.,Science, 282:946-949 (1998).
Ferrara,J. Mol. Med., 77:527-543 (1999).
Ferrara and Alitalo,Nature Med., 5:1359-1364 (1999).
Fidler, et al.,Adv. Cancer Res., 28:149-250 (1978).
Folkman, et al.,Proc. Nat'l. Acad. Sci. USA, 76:5217-5221 (1979).
Fraley, et al.,Proc. Nat'l. Acad. Sci. USA, 76:3348-3352 (1979).
GenBank Accession No. AF106020.
GenBank Accession No. NM—003872.
GenBank Accession No. NM—003873.
GenBank Accession No. NM—005429.
GenBank Accession No. P15692.
GenBank Accession No. S67520.
GenBank Accession No. S67522.
GenBank Accession No. U48801.
GenBank Acession No. XM—003852.
GenBank Accession No. X06374.
GenBank Accession No. X54936.
GenBank Accession No. X61656.
GenBank Accession No. X94216.
Koivunen, et al.,Methods Mol. Biol., 129:3-17 (1999).
Koivunen, et al.,Biotechnol., 18(8):768-74 (1999).
Liotta, et al.,Cancer Treatment Res., 40:223-238 (1988).
Maglione, et al.,Oncogene, 8:925-931 (1993).
Mandriota, et al.,The EMBO Journal, 20:672-682 (2001).
Matthews, et al.,Proc. Nat'l. Acad. Sci. USA, 88:9026-9030 (1991).
Meyer, et al.,The EMBO J., 18:363-374 (1999).
Miles and Miles,J. Physiol., 118:228-257 (1952).
Muller, et al.,Structure, 5:1325-1338 (1997).
Muragaki, et al.,Proc. Nat'l. Acad. Sci.(USA), 92:8763-8767 (1995).
National Institutes of Health http://cancertrials.nci.nih.gov
ews/angio.
Nelson, et al.,J. Cell Biol., 97:244-251 (1983).
Neufeld, et al.,The FASEB J., 13:9-22 (1999).
Nicolson,Biochim. Biophy. Acta, 948:175-224 (1988).
Oh, et al.,Dev. Biol., 188:96-109 (1997).
Ortega, et al.,Fron. Biosci., 4:141-152 (1999).
Pajusola, et al.,Oncogene, 9:3545-3555 (1994).
Pertovaara, et al.,J. Biol. Chem., 269:6271-6274 (1994).
Petrova, et al.,Exp. Cell Res., 253:117-130 (1999).
Risau, et al.,Dev. Biol., 125:441-450 (1988).
Rivera-Baeza, et al.,Neuropeptides, 30:327-333 (1996).
Rosenkranz, et al.,Growth Factors, 16:201-216 (1999).
Schmelz, et al.,Differentiation, 57:97-117 (1994).
Skobe, et al.,Nature Medicine, 7:192-198 (2001).
Smith and Scott,Methods Enzymol., 217:228-257 (1993).
Stacker and Achen,Growth Factors, 17:1-11 (1999).
Stacker, et al.,Nature Medicine, 7:186-191 (2001).
Taipale, et al.,Curr. Top. Microbiol. Immunol., 237:85-96 (1999).
Terman, et al.,Biochem. Biophys. Res. Comm., 187:1579-1586 (1992).
Valtola, et al.,Am. J. Pathol., 154:1381-1390 (1999).
Vassar, et al.,Proc. Nat'l. Acad. Sci. USA, 86:1563-1567 (1989).
Vassar and Fuchs,Genes Dev., 5:714-727 (1991).
Waltenberger, et al.,The J. Biol. Chem., 269:26988-26995 (1994).
Zachary,The Intl. J. Biochem. Cell Biol., 30:1169-1174 (1998).
Zetter,N. Eng. J. Med., 322:605-612 (1990).
Alitalo Kari
Koivunen Erkki
Kubo Hajime
Huynh Phuong
Marshall & Gerstein & Borun LLP
Vegenics Limited
LandOfFree
VEGFR-3 inhibitor materials and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VEGFR-3 inhibitor materials and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGFR-3 inhibitor materials and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111263